Kalvista Pharmaceuticals, Inc. (KALV) — 10-Q Filings
All 10-Q filings from Kalvista Pharmaceuticals, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
KalVista Posts First EKTERLY Revenue, Losses Widen Amid Launch Costs
— Nov 10, 2025 Risk: medium
KalVista Pharmaceuticals, Inc. reported its first product revenue of $13.692 million for the three and nine months ended September 30, 2025, following the FDA a -
KalVista's EKTERLY Launch Drives Revenue, But Losses Widen to $60M
— Sep 11, 2025 Risk: high
KalVista Pharmaceuticals, Inc. reported a net loss of $60.096 million for the three months ended July 31, 2025, a significant increase from the $40.443 million -
KalVista Pharmaceuticals Files 10-Q
— Mar 12, 2025 Risk: medium
KalVista Pharmaceuticals, Inc. filed a 10-Q for the period ending January 31, 2025. The company, formerly known as Carbylan Therapeutics, Inc., is focused on ph -
KalVista Pharmaceuticals Files 10-Q for July 31, 2024
— Sep 5, 2024 Risk: medium
KalVista Pharmaceuticals, Inc. filed its 10-Q for the period ending July 31, 2024. The company, formerly known as Carbylan Therapeutics, Inc., reported its fina -
KalVista Pharmaceuticals, Inc. Files 10-Q for Period Ending January 31, 2024
— Mar 11, 2024 Risk: low
KalVista Pharmaceuticals, Inc. (KALV) filed a Quarterly Report (10-Q) with the SEC on March 11, 2024. KalVista Pharmaceuticals, Inc. filed a 10-Q report for the
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX